{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003502","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.929356+00:00","generated_at":"2026-05-24T06:48:46.334099+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Harmony Biosciences names Takeda veteran Adam Zaeske as CCO; Dierks steps down","bullets":["Jeffrey Dierks steps down as CCO effective March 31, 2025; receives $476,215 cash and accelerated vesting for 2025 awards.","Adam Zaeske appointed as EVP and CCO effective March 31, 2025; previously Head of Central, South, and Eastern Europe at Takeda.","Zaeske managed a $2B business across 25 countries with 900 employees; delivered 3 consecutive years of double-digit growth.","Company reaffirms 2025 revenue guidance and states WAKIX is a $1B+ opportunity in adult narcolepsy alone.","Zaeske brings 25 years of pharma experience, including rare disease and neurology launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003502","json":"https://secwatch.observer/filing/0001558370-25-003502.json","markdown":"https://secwatch.observer/filing/0001558370-25-003502.md","text":"https://secwatch.observer/filing/0001558370-25-003502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/0001558370-25-003502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/hrmy-20250320x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:48:46.334099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d39bb05df5","claim":"Jeffrey Dierks departed as Chief Commercial Officer at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (the “Effective Date”), for personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/0001558370-25-003502-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departing"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}